Mar 1, 8:24 AM

bioMrieux's 2016 Financial Results - Remarkable growth in sales in 2016, up 9.6% at constant exchange rates and scope of consolidation: => 2,103 million in sales=> Up 7.1% as reported - Contributive operating income before non-recurring items: => 298 million, or 14.2% of sales=> Up 14.5% - Earnings per share up 62% year-on-year "... buoyed by the commitment of Alexandre Mrieux and backed by the expertise and dedication of our teams, we will continue to invest in our future in 2017 to best serve our customers, patients and public health mission." said Jean-Luc Belingard, bioMrieux Chairman. More: http://www.biomerieux.com/en/biomerieux-2016-financial-results-0

Mar 1, 7:57 AM

bioMrieuxs VIDAS BRAHMS PCT becomes the first FDA-cleared procalcitonin assay as an aid for antibiotic stewardship in respiratory infections and sepsis. "... This FDA clearance illustrates our capacity to provide clinicians with high medical value tests to help them make important treatment decisions. The goal is to achieve better outcomes for patients and to ensure that each of them receives the appropriate treatment, said Mark Miller, Corporate VP, Chief Medical Officer at bioMrieux. More: http://www.biomerieux.com/en/biomerieuxs-vidasr-brahms-pcttm-becomes-first-fda-cleared-procalcitonin-assay-aid-antibiotic

Jan 13, 7:23 PM

Just in.... bioMrieux Americas team getting excited about serving our customers and public health in 2017! Go team, Go!

Nov 26, 5:53 AM